PACIFIC-III: CCTA and Dynamic CT Perfusion for the Diagnosis of Myocardial Ischemia in Patients With Coronary Stents

Sponsor
Amsterdam UMC, location VUmc (Other)
Overall Status
Recruiting
CT.gov ID
NCT04742933
Collaborator
(none)
140
1
29.2
4.8

Study Details

Study Description

Brief Summary

A single centre prospective trial in which patients with a prior PCI for stable CAD who are referred for invasive angiography will undergo state-of-the art CCTA and dynamic CT perfusion. Subsequently invasive FFR and iFR measurements will be routinely performed in each coronary vessel.

Condition or Disease Intervention/Treatment Phase
  • Other: There is no intervention in this observational trial

Detailed Description

Rationale: Recent development in computed tomography (CT) hardware have fulfilled the prerequisites for clinical CT myocardial perfusion imaging (CTP). Cardiac CT, has by means of coronary computed tomography angiography (CCTA) and novel techniques such as CTP the unique ability to provide information on both the anatomical and functional severity of coronary artery disease (CAD). However, diagnostic performance of these novel techniques when referenced by the clinical diagnostic standard, invasive fractional flow reserve (FFR) measurements, has scarcely been investigated in patients with a prior PCI.

Objective: To determine the diagnostic performance of CCTA and dynamic CTP for the diagnosis of myocardial ischemia using invasive coronary indices as the reference standard.

Study design: The study is a single-center prospective comparative trial in which all patients will undergo CCTA and dynamic CTP before invasive coronary angiography (ICA) in conjunction with invasive flow/pressure measurements.

Study population: Patients referred for a diagnostic ICA with a prior of PCI for stable CAD will be evaluated for inclusion in the study.

Main study parameters/endpoints: Hemodynamic significant CAD as defined by an FFR ≤0.80 / iFR < 0.90. Sensitivity, specificity, negative predictive value, positive predictive value and accuracy will be assessed for CCTA and dynamic CTP. In addition, this study will assess the prognostic value of CCTA and dynamic CTP in patients with a prior cardiac revascularization.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: A two day protocol will be completed after referral ensuring the diagnostic work-up of patients is not delayed. On day 1 patients will undergo CCTA and CTP. Then, on day 2, irrespective of CT results, patients will undergo ICA with invasive pressure measurements. The risks of CT are considered to be low. Patients are referred for a clinically indicated ICA and as such risks of the ICA are not deemed study-related. Future patients might benefit from the present study as combined anatomical information (CCTA) and functional information (dynamic CTP) might lead to a more judicious referral for ICA which leads to a reduction of exposure to invasive procedures such as ICA in combination with invasive pressure measurements.

Study Design

Study Type:
Observational
Anticipated Enrollment :
140 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Head-to-Head Prospective Comparison of Diagnostic Accuracy of CCTA and Dynamic CT Perfusion in Patients With Prior PCI for the Diagnosis of Myocardial Ischemia as Defined by Invasive Flow and Pressure Indices - PACIFIC-III
Anticipated Study Start Date :
Oct 25, 2021
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Apr 1, 2024

Outcome Measures

Primary Outcome Measures

  1. Sensitivity and Specificity of Dynamic CT-perfusion and CCTA for CAD [3 years]

    FFR will be used as a reference standard, the primary endpoint is an abnormal FFR =< 0.80. Diagnostic study using FFR as endpoun

Secondary Outcome Measures

  1. Major adverse cardiac events, cardiac death or repeat revascularization [3 years]

    The secondary endpoint is to assess the prognostic value of CT in patients with a prior history of PCI

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • History of PCI for stable CAD

  • Referred for a diagnostic ICA.

  • Age above 30 years.

Exclusion Criteria:
  • History of severe COPD or chronic asthma

  • Pregnancy

  • Renal failure (eGFR <30 mL/min)

  • Use of sildenafil (Viagra) or dipyramidol (Persantin) that cannot be terminated

  • Contra-indications for β-blockers

  • Allergic reaction to iodized contrast

  • Concurrent or prior (within last 30 days) participation in other research studies using investigational drugs

  • Claustrophobia

  • Significant co-morbidities

  • Atrial fibrillation, second or third degree atrioventricular block

  • Tachycardia

  • Acute myocardial infarction

  • History of CABG

  • Heart failure

  • Cardiomyopathies

  • Previous radiation exposure in the diagnostic work-up

  • Unable to give informed consent

  • Indispensable follow-up with (serial) CT scans for non-cardiac related condition

Contacts and Locations

Locations

Site City State Country Postal Code
1 Amsterdam UMC, location VUMC Amsterdam Netherlands 1081 HV

Sponsors and Collaborators

  • Amsterdam UMC, location VUmc

Investigators

  • Principal Investigator: Paul Knaapen, MD, PhD, Amsterdam UMC, location VUmc
  • Principal Investigator: Ibrahim Danad, MD, PhD, Amsterdam UMC, location VUmc

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ibrahim Danad, MD, Principal Investigator, Amsterdam UMC, location VUmc
ClinicalTrials.gov Identifier:
NCT04742933
Other Study ID Numbers:
  • VUmc_2020-4973
First Posted:
Feb 8, 2021
Last Update Posted:
Oct 12, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ibrahim Danad, MD, Principal Investigator, Amsterdam UMC, location VUmc
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 12, 2021